Zenas BioPharma (ZBIO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Zenas BioPharma (ZBIO) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.00 of bullish evidence against -0.36 bearish.

Zenas BioPharma last closed at $28.30, +1.29% on the session.

Against the IVW growth benchmark the position is +0.37% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

15 graded predictions for ZBIO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Zenas BioPharma in the 5th percentile on return on equity, where 100 is best.

Zenas BioPharma is classified under Health Care / Biotechnology, with a market capitalisation of $1.84B.

StockMap tracks Zenas BioPharma as the 95th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Zenas BioPharma ranks 295th of 344 in the group, against a group median of -0.21.